Mayne Pharma’ Nextstellis Receives the US FDA’s Approval for the Prevention of Pregnancy

 Mayne Pharma’ Nextstellis Receives the US FDA’s Approval for the Prevention of Pregnancy

Shots:

  • The FDA has approved Nextstellis (3 mg, DRSP, and 14.2 mg, E4 tablets) for the prevention of pregnancy and is expected to be commercially available in Jun’2021
  • The P-III study demonstrated the efficacy of Nextstellis across all subgroups through age, BMI and prior hormonal contraception use. The therapy is also associated with favorable bleeding control, including in cycle 1.
  • Nextstellis is the 1st oral contraceptive pill containing E4 and is safe, effective, and well-tolerated in clinical trials with a desirable bleeding profile and minimal impact on triglycerides, cholesterol, glucose, as well as weight and endocrine markers

Click here ­to­ read full press release/ article | Ref: PRNewswire| Image: Mayne Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post